BAX · NYSE · STOCK
Baxter International (BAX) Stock Analysis
$25.27
52W $15.73 – $30.00
53/100
$13.32B
-12.6
0.65
Is BAX Bullish or Bearish?
Mixed.
Innellis AI committee rates Baxter International (BAX) Watch with a composite score of 53/100
, based on 6 analysts with 50% agreement.
Last updated October 16, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.24 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.76 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — high leverage (debt-to-equity 1.55) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- Dividend yield of 3.2% pays you to wait — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -16.6% -- cheap may mean cheap for a reason — Value
- Debt-to-equity of 1.55 adds balance-sheet risk to the value case — Value
- RSI at 79 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- High leverage (debt-to-equity 1.55) amplifies downside in a stress scenario — Risk
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of October 16, 2026
Overall Committee Score
53/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 85%
of 192 Healthcare peers
Value Analyst
bearish
40
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
+ Dividend yield of 3.2% pays you to wait
− ROE of only -16.6% -- cheap may mean cheap for a reason
Growth Analyst
bullish
62
/ 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 79 is in overbought territory
Risk Analyst
bearish
30
/ 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 1.55) amplifies downside in a stress scenario
Macro Analyst
bullish
65
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst
bullish
61
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager
bearish
30
/ 100 · Moderate confidence
The existing book itself argues for caution here, independent of how good this specific stock looks
− Sector concentration is already high (HHI 2739.42)
Investment Thesis Evolution
Committee score moved marginally from 53.9 to 52.8.
- New bearish signals: 3 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
- Analyst(s) changed stance: News Analyst, Technical Analyst.
Analyst-level changes:
- News Analyst: stance neutral->bullish; score 58->61 (+3).
- Portfolio Manager: +1 bearish signal(s).
- Technical Analyst: stance bullish->neutral; score 68->58 (-10); +2 bearish signal(s).
Comparing 2026-10-15 to 2026-10-16 (1 day apart).
Technical Analysis
RSI (14)
78.7
Overbought
MACD Histogram
0.254
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$21.59
Resistance
$30.00
Bollinger %B
1.12
Above Upper Band
Price vs Moving Averages
EMA 9
$24.67
Above
EMA 21
$24.37
Above
EMA 50
$24.25
Above
EMA 200
$22.70
Above
Fundamental Analysis
Valuation
97
Growth
69
Profitability
6
Financial Health
71
Cash Flow
70
Valuation
P/E Ratio
-12.6×
P/B Ratio
2.15×
PEG Ratio
0.15
Dividend Yield
0.16%
52W High
$30.00
52W Low
$15.73
Quality & Growth
ROE
-1561.4%
ROA
-477.2%
Gross Margin
3007.8%
Operating Margin
-238.9%
Revenue Growth YoY
—
Debt / Equity
1.56
AI Fundamental Assessment
P/E ratio of -12.6 (inexpensive relative to a 15-40x range); Price-to-book of 2.1x; PEG ratio of 0.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -15.6%; Return on assets of -4.8%; Net margin of -9.3%; Gross margin of 30.1%; Current ratio of 1.95 (healthy short-term liquidity); Debt-to-equity of 1.56; Free cash flow per share is positive (1.31); Most recent quarter beat estimates by 51.5%; 2 consecutive earnings beats; EPS growth accelerating (-18.2% -> +55.6% QoQ); Average YoY EPS growth of -5.1%; Analyst estimates falling over recent quarters
Get the Full BAX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →